- Home
- NSTS vs RLYB Comparison
NSTS vs RLYB Comparison
Compare NSTS & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NSTS
- RLYB
- Stock Information
- Founded
- NSTS 1921
- RLYB 2018
- Country
- NSTS United States
- RLYB United States
- Employees
- NSTS N/A
- RLYB N/A
- Industry
- NSTS Savings Institutions
- RLYB Biotechnology: Pharmaceutical Preparations
- Sector
- NSTS Finance
- RLYB Health Care
- Exchange
- NSTS Nasdaq
- RLYB Nasdaq
- Market Cap
- NSTS 51.2M
- RLYB 46.1M
- IPO Year
- NSTS N/A
- RLYB 2021
- Fundamental
- Price
- NSTS $10.35
- RLYB $1.11
- Analyst Decision
- NSTS
- RLYB Buy
- Analyst Count
- NSTS 0
- RLYB 6
- Target Price
- NSTS N/A
- RLYB $8.30
- AVG Volume (30 Days)
- NSTS 9.9K
- RLYB 50.0K
- Earning Date
- NSTS 11-11-2024
- RLYB 11-07-2024
- Dividend Yield
- NSTS N/A
- RLYB N/A
- EPS Growth
- NSTS N/A
- RLYB N/A
- EPS
- NSTS N/A
- RLYB N/A
- Revenue
- NSTS $5,570,000.00
- RLYB $299,000.00
- Revenue This Year
- NSTS N/A
- RLYB N/A
- Revenue Next Year
- NSTS N/A
- RLYB N/A
- P/E Ratio
- NSTS N/A
- RLYB N/A
- Revenue Growth
- NSTS N/A
- RLYB N/A
- 52 Week Low
- NSTS $8.52
- RLYB $1.08
- 52 Week High
- NSTS $10.80
- RLYB $4.60
- Technical
- Relative Strength Index (RSI)
- NSTS 56.42
- RLYB 47.41
- Support Level
- NSTS $10.06
- RLYB $1.09
- Resistance Level
- NSTS $10.55
- RLYB $1.18
- Average True Range (ATR)
- NSTS 0.30
- RLYB 0.04
- MACD
- NSTS 0.03
- RLYB 0.00
- Stochastic Oscillator
- NSTS 65.38
- RLYB 22.22
About NSTS NSTS Bancorp Inc.
NSTS Bancorp Inc is a savings and loan holding company regulated Federal Reserve Board. The company was formed to serve as the North Shore Trust and Savings stock holding company. The Bank is a wholly-owned subsidiary of the company and operates as a traditional savings institution focused on serving the banking needs of customers in our market area of Lake County, Illinois and adjacent communities.
About RLYB Rallybio Corporation
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. Its program is for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.